Skip to main content
. 2011 Jan 21;60(2):525–536. doi: 10.2337/db09-1305

FIG. 3.

FIG. 3.

PancMet KO mice treated with MLDS display (A) significantly increased blood glucose levels (^P < 0.05 vs. WT) and (B) a trend toward faster and higher frequency of hyperglycemia (>200 mg/dL on at least two consecutive measurements), although not significant (P = 0.084 at day 12 and P = 0.154 at days 16 and 20 determined by Fisher exact test). On the other hand, PancMet KO mice display a significantly faster and higher frequency of severe hyperglycemia (>300 mg/dL on at least two consecutive measurements) compared with WT mice (day 16, PancMet KO 100% vs. WT 10%, P = 0.002; day 20, PancMet KO 100% vs. WT 20%, P = 0.007). C: PancMet KO mice treated with MLDS display profound hypoinsulinemia at day 20 (*P < 0.05 vs. untreated and ^P < 0.05 vs. WT). WT (n = 10) and PancMet KO mice (n = 5) were injected with 40 mg/kg STZ for 5 days.